Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 December 2022 | Story Jóhann Thormählen | Photo Anja Aucamp
Peter Makgato
Peter Makgato showed true perseverance in coming back after being out of action for more than a year with an Achilles tendon injury. The Kovsie long jumper won a bronze medal at the South African Championships in 2022.

If it wasn’t for Peter Makgato’s UFS support system, he would have been lost to South African athletics. The road of recovery after a serious injury can be lonesome, but he was never alone.

The promising long jumper had to learn to walk again after the injury to his Achilles tendon and could only compete more than a year after his dreams were shattered in November 2020.

Only months after returning to jumping in 2022, he was winning medals again.

Keeping me focused

“Without KovsieSport, I believe I would have hung up my spikes after that injury,” says Makgato. “Throughout the entire journey back, I had support from my coach (Emmarie Prinsloo; Head of KovsieSport Jumping Academy) and Oom DB (Prinsloo; Head of Athletics at KovsieSport).”

He also praises “the expert medical help” from Kovsie Health and says he went through nothing alone. “My progress was monitored by a team that knew me before the injury and this meant they were able to keep me focused on the progress and not on the injury.”

Although he had injuries before, Makgato says the emotional challenges were much bigger. “What really helped me were a few words from Wayde van Niekerk days after my operation when I went back to the track on crutches. He told me not to lose my head.

“That is the best advice you can give someone in my position. Physically I was broken, I had to make sure that mentally I fought to stay above the waters.”

Bigger goals in mind

He was only able to walk again from May 2021, started rehab in August 2021, and was running properly by December 2021.

He was only able to jump competitively again in March 2022, and a month later claimed a bronze medal at the South African Championships (7,47 m). This was followed by a USSA bronze in May 2022 (7,46 m).

“I had bigger goals in mind. Now that I look back, I realise that for a person who could not even run properly five months before and who had little preparation time, I was doing pretty good.”

And now the Master of Laws student has his sights on bigger things again: The World Athletics Championships next year and the Olympic Games in 2024.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept